Nanobiotix (NASDAQ:NBTX) Shares Gap Up - Still a Buy?

Key Points

• Shares gapped up, opening at $33.79 versus the prior close of $31.16 and last trading around $33.37 on volume of 8,157 shares, with a 50‑day moving average of $31.69 and a 200‑day moving average of $25.25.
• Analyst sentiment is mixed-to-positive: four Buys, one Hold and one Sell give a consensus rating of “Moderate Buy” with an average target of $26.67, while notable moves include Guggenheim raising its target to $36 and UBS to $30 as Weiss Ratings kept a Sell.
• Nanobiotix is a clinical‑stage biotech developing NBTXR3, a hafnium‑oxide radioenhancer with a CE Mark for soft tissue sarcoma; the company reported a quarterly loss of $0.23 EPS on $3.42M revenue, while analysts expect full‑year EPS of $0.53.

Shares of Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX - Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $31.16, but opened at $33.79. Nanobiotix shares last traded at $33.3740, with a volume of 8,157 shares changing hands.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on NBTX. Weiss Ratings reissued a "sell (d-)" rating on shares of Nanobiotix in a research report on Tuesday, April 21st. Guggenheim upped their price target on Nanobiotix from $26.00 to $36.00 and gave the company a "buy" rating in a research report on Thursday, April 2nd. UBS Group upped their price target on Nanobiotix from $3.50 to $30.00 and gave the company a "neutral" rating in a research report on Friday. Finally, TD Cowen reissued a "buy" rating on shares of Nanobiotix in a research report on Thursday, March 12th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $26.67.

Nanobiotix Stock Performance

The stock has a 50 day moving average of $31.69 and a 200 day moving average of $25.25.

Nanobiotix (NASDAQ:NBTX - Get Free Report) last issued its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The company had revenue of $3.42 million during the quarter. On average, analysts anticipate that Nanobiotix S.A. - Sponsored ADR will post 0.53 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in NBTX. Royal Bank of Canada grew its stake in Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company's stock worth $61,000 after buying an additional 2,500 shares during the last quarter. Optiver Holding B.V. acquired a new position in Nanobiotix during the 3rd quarter worth $101,000. Marshall Wace LLP acquired a new position in Nanobiotix during the 4th quarter worth $220,000. Finally, Millennium Management LLC acquired a new position in Nanobiotix during the 4th quarter worth $390,000. 38.81% of the stock is currently owned by institutional investors.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company's lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.